Novo Nordisk (NVO)
NVOPrice: $36.75
Fair Value: 🔒
🔒score
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obe... more
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufactu... more
Description
Shares
| Market Cap | $163.32B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | DK | CEO | Maziar Mike Doustdar |
| IPO Date | 1981-04-30 | CAGR | 0.11% |
| Employees | 77,406 | Website | www.novonordisk.com |
| Div. Yield | 80.65% | Payout Ratio | 0.51% |
| Buy Back Yield | 13.07% | Total Yield | 93.72% |
NVO chart loading...
Fundamentals
Technicals
| Enterprise Value | $1513.28B | P/E Ratio | 10.32 |
| Forward P/E | 1.67 | PEG Ratio | -2.2 |
| P/S Ratio | 0.21 | P/B Ratio | 0.33 |
| P/CF Ratio | 0.54 | P/FCF Ratio | 1.15 |
| EPS | $3.56 | EPS Growth 1Y | 1.81% |
| EPS Growth 3Y | 88.31% | EPS Growth 5Y | 155.6% |
| Revenue Growth 1Y | 2.34% | Gross Margin | 0.81% |
| Operating Margin | 0.41% | Profit Margin | 0.33% |
| ROE | 0.61% | ROA | 0.19% |
| ROCE | 0.39% | Current Ratio | 0.8 |
| Quick Ratio | 0.57 | Cash Ratio | 0.12 |
| Debt/Equity | 0.67 | Interest Coverage | 18.86 |
| Altman Z Score | 4.07 | Piotroski Score | 6 |